ClinicalTrials.gg
CompletedNCT03461380Updated Apr 28, 2020

Effect of Menopause Relief EP-40 in Women With Menopausal Symptoms

A Phase 2 interventional study of Menopause Relief EP-40 and Low Dose Black Cohosh in Menopause, sponsored by EuroPharma, Inc.. Completed at 1 site in Georgia. Open to female participants aged 41 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-04-28.

Sponsored by EuroPharma, Inc. · Phase 2, Interventional, and Treatment

Phase
Phase 2
Study type
Interventional
Enrollment
220
Allocation
Randomized
Ages
41 Years and older
Sex
Female
01

Study summary

This study compares the efficacy of a fixed combination of black cohosh (EP-40) and Rhodiola rosea (EPR-7) with low (6.5 mg) and high doses (500 mg) of a standardized black cohosh extract only in adult woman with menopausal complaints.

Read the detailed description

Due to the problems caused by Hormone Replacement Therapy with chemical entities, some medicinal plants used in the traditional systems of medicine have shown immense potential in non-hormonal treatment of menopausal symptoms without major adverse events. We hypothesize that Menopause Relief EP-40 (a fixed combination of Cimicifuga EP-40 and Rhodiola EPR-7 extracts) will significantly relieve menopausal complaints such as hot flushes, profuse sweating hot flushes, excessive perspiration, night sweats, sleep disorders, nervousness, mood swings, physical and mental fatigue as compared to EP-40® capsules or placebo in adult females in menopause.

02

Conditions studied

  • Menopause

Keywords

  • Cimicifuga, Rhodiola, Menopause Symptoms
03

In context

Lead sponsor

EuroPharma, Inc. is the lead sponsor of 8 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
41 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of menopausal female climacteric states (N95.1 according to the International Statistical Classification of Diseases and Related Health Problems 10th Revision, ICD-10, Version for 2014) which is characterized by symptoms such as flushing, sleeplessness, headache, lack of concentration associated with menopause, etc
  • Patients suffering from menopausal syndrome with neurovegetative components which have been stable anamnestically during the last 2 weeks
  • No medication taken for management of menopausal syndrome with neurovegetative components during the last 4 weeks
  • Ability to understand and provide signed
  • Ability to participate in the study
  • In some cases, diagnosis should be confirmed by blood tests of follicle-stimulating hormone (≥ 40 IU/L) [ status], thyroid function with normal serum free T4 (fT4), estrogen (estrodiol levels) [premenopausal 30-400 pg/mL; after menopause \<30 pg/mL]

Exclusion criteria

Exclusion Criteria:

  • subjects with previous or current psychological disease that could interfere with their ability to participate in the study
  • anamnestic or current alcohol or drug abuse
  • concomitant treatment with psychotropic (in particular benzodiazepines, antidepressants, hypnotics or neuroleptics, tamoxifen, clomiphene, and danazol) or hormonally acting drugs such as hormone replacement therapy (HRT)
  • hyperthyroidism
  • malignant tumors
  • continuous climacteric bleeding and complaints related to myomas
  • patients who have taken another experimental drug within a 4-week period prior to the trial
  • pregnancy/lactation
  • serious internal disease
  • previous organ transplantation
  • premenopausal women with insufficient protection
  • to one of the ingredients of the trial medication
  • a of >30
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
220 participants (actual)

Study arms

  • Experimental
    Menopause Relief EP-40

    Fixed combination of black cohosh EP-40 and Rhodiola rosea EPR-7 206.5 mg orally twice daily; daily dose 413 mg of active ingredients

    Dietary Supplement: Menopause Relief EP-40

  • Active comparator
    High Dose Black Cohosh

    Black cohosh 500 mg orally twice daily; daily dose 1000 mg of active ingredient

    Dietary Supplement: High Dose Black Cohosh

  • Placebo comparator
    Placebo

    Placebo capsule 600 mg excipients orally twice daily

    Dietary Supplement: Placebo

  • Active comparator
    Low Dose Black Cohosh

    Black cohosh 6.5 mg orally twice daily; daily dose 13 mg of active ingredient

    Dietary Supplement: Low Dose Black Cohosh

Interventions

  • Dietary supplementMenopause Relief EP-40

    Fixed combination of black cohosh and Rhodiola rosea

  • Dietary supplementLow Dose Black Cohosh

    6.5 mg black cohosh

  • Dietary supplementHigh Dose Black Cohosh

    500 mg black cohosh

  • Dietary supplementPlacebo

    600 mg excipient

06

What researchers measure

Primary outcomes

  1. Kupperman Menopausal Index (KMI)

    A modified total Kupperman Index (KMI) score and its sub-items will be used. It is a 10-item questionnaire of single symptoms with scores ranging from 0 to 3 (none, mild, moderate and severe). Total KMI is defined as the sum of sub-item scores multiplied by any weighting factors. The maximum value of the total KMI is 48. The primary outcome will be the difference in the changes from baseline to the end of therapy (week 12), between verum groups and placebo, assessed by the total KMI and stratified by individual baseline scores in an intention-to-treat (ITT) analysis (patients treated with study medication and with at least one efficacy assessment after baseline).

    Time frame: 12 weeks

  2. Menopause Rating Scale (MRS)

    The MRS is a patient reported assessment of 11 symptoms of menopause on a scale of 0 (none) to 4 (very severe). The MRS groups symptoms into three subscales: psychological, somatic, and urogenital. A composite score is calculated by adding the items in each dimension (subscale). The total score is the sum of the three dimensional scores. The primary outcome will be the difference in the changes from baseline to the end of therapy (week 12), between both verum groups and placebo, assessed by the MRS and stratified by individual baseline scores in an intention-to-treat (ITT) analysis (patients treated with study medication and with at least one efficacy assessment after baseline).

    Time frame: 12 weeks

07

Study locations

1 site
  • I.Zhordania Institute of Reproductology
    Tbilisi, Georgia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 28, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03461380
Lead sponsor
EuroPharma, Inc.
Collaborators
I.Zhordania Institute of Reproductology
Responsible party
Sponsor
First posted
Mar 12, 2018
Start date
Oct 1, 2018
Primary completion
Sep 30, 2019
Completion
Oct 1, 2019
Last update
Apr 28, 2020

Study contacts

Lali Phkhaladze, PhD, MD
principal investigator · I.Zhordania Institute of Reproductology, Tevdore Mgvdeli Street, Tbilisi, Georgia

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Black cohosh root extract

Start the discussion